Sleep Medications During Sleep Studies
Patients should generally NOT take their usual sleep medications during diagnostic polysomnography (PSG) for sleep disorders like sleep apnea or narcolepsy, as these medications can interfere with accurate diagnosis. 1
Why Sleep Medications Should Be Avoided During Diagnostic Sleep Studies
Polysomnography is not indicated for diagnosing insomnia disorder, and primary care clinicians make diagnostic and treatment decisions based on patient-reported sleep concerns, not sleep laboratory findings. 1 This is a critical distinction—sleep studies are performed to diagnose conditions like sleep apnea, narcolepsy, and other primary sleep disorders, not to evaluate insomnia itself.
Impact on Sleep Architecture and Diagnostic Accuracy
- Sleep medications alter sleep architecture and respiratory parameters, which can mask or distort the underlying sleep disorder being evaluated. 2
- Zolpidem and eszopiclone affect polysomnographic variables including sleep efficiency, wake after sleep onset, and total sleep time, potentially obscuring the true severity of conditions like obstructive sleep apnea. 3, 4, 5
- Individual responses to sleep medications are highly variable, making interpretation of sleep study results unreliable when medications are on board. 6
Specific Effects on Sleep Apnea Diagnosis
- Zolpidem has variable effects on apnea-hypopnea index in unselected sleep apnea patients, with no systematic difference in respiratory parameters, making accurate severity assessment impossible. 6
- Zolpidem increases arousal threshold, which is one of the phenotypic traits contributing to obstructive sleep apnea—this can paradoxically worsen apnea severity in some patients while masking arousals that would normally be counted. 6
- Eszopiclone pre-medication resulted in higher apnea-hypopnea index at final CPAP pressure and increased likelihood of unacceptable titration studies. 7
When Sleep Medications Were Used in Research Settings
The evidence shows that when sleep medications were used during polysomnography, it was only in research studies specifically designed to evaluate the medications themselves, not to diagnose other sleep disorders:
- Studies evaluating zolpidem efficacy used PSG on specific treatment nights to measure drug effects on sleep latency, total sleep time, and sleep efficiency—not to diagnose underlying sleep disorders. 3, 4
- Eszopiclone trials conducted PSG to assess medication efficacy, with polysomnography performed on final treatment nights or at specific intervals during drug trials. 3, 5
- These were controlled research conditions where the goal was measuring medication effects, not diagnosing sleep pathology. 3
Clinical Practice Implications
If a patient requires sleep medication to sleep in the laboratory, this suggests several possibilities:
- The patient may have severe insomnia that should be addressed with cognitive behavioral therapy for insomnia (CBT-I) before attempting diagnostic sleep studies. 1
- The sleep study may need to be rescheduled after addressing the insomnia component separately. 1
- If medications are absolutely necessary, the interpreting physician must be informed and results interpreted with extreme caution, understanding that diagnostic accuracy is compromised. 2
Important Caveats
- Medication effects on sleep are difficult to predict and may differ between acute and chronic use, in normal individuals versus those who are ill, and with medication interactions. 2
- Most medications have not been sufficiently studied to determine their primary effects on sleep and waking behavior during diagnostic testing. 2
- The interaction of sleep medications with underlying sleep disorders (like sleep apnea) can be unpredictable and potentially dangerous, as sedatives may worsen respiratory events. 6